Generalized Anxiety Disorder 7

Last updated

Generalized Anxiety Disorder 7 item
Synonyms GAD-7
LOINC 69737-5

The Generalized Anxiety Disorder 7 (GAD-7) is a widely used self-administered diagnostic tool designed to screen for and assess the severity of generalized anxiety disorder (GAD). [1] Comprising seven items, the GAD-7 measures the frequency of anxiety symptoms over the past two weeks, with respondents rating each item on a scale from "not at all" to "nearly every day." Developed by Dr. Robert L. Spitzer and colleagues, [1] the GAD-7 is commonly used in both clinical settings and research to identify GAD and to monitor treatment outcomes. It is valued for its simplicity, reliability, and validity in detecting anxiety symptoms in diverse populations.

Contents

The GAD-7 is normally used in outpatient and primary care settings for referral to a psychiatrist pending outcome. [2] A systematic review compared screening tools and concluded that the GAD-7 is the most efficient one for identifying GAD as well as panic disorders in primary care populations. [3]

Criteria

The GAD-7 has seven items, which measure severity of various signs of GAD according to reported response categories with assigned points. [2] The GAD-7 items include:

  1. Nervousness
  2. Inability to stop worrying
  3. Excessive worry
  4. Restlessness
  5. Difficulty in relaxing
  6. Easy irritation
  7. Fear of something awful happening [4]

Response options range from “not at all” (= 0 points), “several days” (= 1 point), “more than half the days” (= 2 points), and “nearly every day” (= 3 points) with a score range from 0-21 points. [1]

Interpretation of results

The assessment is indicated by the total score, which is made up by adding together the scores for the scale of all seven items with responses getting 0 to 3 points:

The normative data enable users of the GAD-7 to discern whether an individual's anxiety score is normal, or mildly, moderately, or severely elevated. [6] However, while the GAD-7 seem to be able to provide probable cases of GAD, it cannot be used as replacement for clinical assessment and additional evaluation should be used to confirm a diagnosis of GAD. [1] [7]

ScoreRisk LevelSuggested Intervention
0-4No to Low riskNone
5-9MildRepeat on follow-up
10-14ModerateFurther evaluation required. Consider adjusting treatment plan.
15+SevereAdjust treatment plan. Higher level of care needed. Pharmacology re-evaluation.

Reliability and validity

The GAD-7 was originally validated in a primary care sample and a cutoff score of 10 (which the authors considered optimal) had a sensitivity value of 0.89 and a specificity value of 0.82 for identifying GAD. The authors of the questionnaire also found acceptable sensitivity and specificity values when the questionnaire was used as a general screen to identify other anxiety disorders (Panic Disorder, Social Anxiety, and PTSD) (GAD-7, score ≥ 8: sensitivity: 0.77, specificity: 0.82). [8]

The GAD-7 has further been studied and validated in numerous other samples and settings. [9] It has been shown to correlate with other measures of anxiety and has been considered superior to other questionnaires. [10] [11] [12] The GAD-7 has been evaluated in samples of both children and young individuals [13] as well as older adults. [14] It has been used in more than 2500 peer reviewed publications indexed in PubMed (current search here). The consensus is that it can efficient tool for screening for GAD and assessing its severity in clinical practice and research. [15] A meta-analysis found that it achieved acceptable accuracy at a cutoff point of 8 (sensitivity of 0.83, specificity: 0.84, pooling 12 samples and 5223 participants). [16]

The use of sumscores (i.e. summing the scores of each item) is supported by psychometric studies in some contexts, but using techniques based on factor analysis are deemed more precise. [17]

See also

Related Research Articles

Psychological testing refers to the administration of psychological tests. Psychological tests are administered or scored by trained evaluators. A person's responses are evaluated according to carefully prescribed guidelines. Scores are thought to reflect individual or group differences in the construct the test purports to measure. The science behind psychological testing is psychometrics.

Generalized anxiety disorder (GAD) is a mental and behavioral disorder, specifically an anxiety disorder characterized by excessive, uncontrollable and often irrational worry about events or activities. Worry often interferes with daily functioning, and individuals with GAD are often overly concerned about everyday matters such as health, finances, death, family, relationship concerns, or work difficulties. Symptoms may include excessive worry, restlessness, trouble sleeping, exhaustion, irritability, sweating, and trembling.

The Beck Depression Inventory, created by Aaron T. Beck, is a 21-question multiple-choice self-report inventory, one of the most widely used psychometric tests for measuring the severity of depression. Its development marked a shift among mental health professionals, who had until then, viewed depression from a psychodynamic perspective, instead of it being rooted in the patient's own thoughts.

The Hamilton Rating Scale for Depression (HRSD), also called the Hamilton Depression Rating Scale (HDRS), sometimes also abbreviated as HAM-D, is a multiple-item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery. Max Hamilton originally published the scale in 1960 and revised it in 1966, 1967, 1969, and 1980. The questionnaire is designed for adults and is used to rate the severity of their depression by probing mood, feelings of guilt, suicide ideation, insomnia, agitation or retardation, anxiety, weight loss, and somatic symptoms.

The Liebowitz Social Anxiety Scale (LSAS) is a short questionnaire developed in 1987 by Michael Liebowitz, a psychiatrist and researcher at Columbia University and the New York State Psychiatric Institute. Its purpose is to assess the range of social interaction and performance situations feared by a patient in order to assist in the diagnosis of social anxiety disorder. It is commonly used to study outcomes in clinical trials and, more recently, to evaluate the effectiveness of cognitive-behavioral treatments. The scale features 24 items, which are divided into two subscales. 13 questions relate to performance anxiety and 11 concern social situations. The LSAS was originally conceptualized as a clinician-administered rating scale, but has since been validated as a self-report scale.

The Yale–Brown Obsessive–Compulsive Scale (Y-BOCS) is a test to rate the severity of obsessive–compulsive disorder (OCD) symptoms.

<span class="mw-page-title-main">Beck Anxiety Inventory</span> Psychological assessment tool

The Beck Anxiety Inventory (BAI) is a formative assessment and rating scale of anxiety. This self-report inventory, or 21-item questionnaire uses a scale ; the BAI is an ordinal scale; more specifically, a Likert scale that measures the scale quality of magnitude of anxiety.

A depression rating scale is a psychometric instrument (tool), usually a questionnaire whose wording has been validated with experimental evidence, having descriptive words and phrases that indicate the severity of depression for a time period. When used, an observer may make judgements and rate a person at a specified scale level with respect to identified characteristics. Rather than being used to diagnose depression, a depression rating scale may be used to assign a score to a person's behaviour where that score may be used to determine whether that person should be evaluated more thoroughly for a depressive disorder diagnosis. Several rating scales are used for this purpose.

<span class="mw-page-title-main">Daily Assessment of Symptoms – Anxiety</span> Questionnaire to assess anxiety levels

The Daily Assessment of Symptoms – Anxiety (DAS-A) questionnaire was specifically developed to detect reduction of anxiety symptoms in patients with generalized anxiety disorder (GAD) during the first week of treatment. It is also meant to help those suffering from certain symptoms identify and recognize that they are experiencing anxiety. This assessment can often reduce anxiety in patients due to the diagnosis and results at the end.

The Bipolar Spectrum Diagnostic Scale (BSDS) is a psychiatric self-rating scale created by Ronald Pies in screening for bipolar disorder (BD). Its initial version consists of a descriptive narrative aimed to capture the nuances and milder variants of BD. Upon revision by Nassir Ghaemi and colleagues, the scale was developed into two sections for a total of 20 questions. The BSDS is widely accepted as an important measure of bipolar disorder alongside other diagnostic tools such as the Mood Disorder Questionnaire and the Bipolar Depression Rating Scale.

Social Phobia Inventory (SPIN) is a questionnaire developed by the department of Psychiatry and Behavioral Sciences of Duke University for screening and measuring severity of social anxiety disorder. This self-reported assessment scale consists of 17 items, which cover the main spectrum of social phobia such as fear, avoidance, and physiological symptoms. The statements of the SPIN items indicate the particular signs of social phobia. Answering the statements a person should indicate how much each statement applies to him or her.

The Patient Health Questionnaire (PHQ) is a multiple-choice self-report inventory that is used as a screening and diagnostic tool for mental health disorders of depression, anxiety, alcohol, eating, and somatoform disorders. It is the self-report version of the Primary Care Evaluation of Mental Disorders (PRIME-MD), a diagnostic tool developed in the mid-1990s by Pfizer Inc. The length of the original assessment limited its feasibility; consequently, a shorter version, consisting of 11 multi-part questions - the Patient Health Questionnaire was developed and validated.

Driving phobia, driving anxiety, vehophobia, amaxophobia or driving-related fear (DRF) is a pathological fear of driving. It is an intense, persistent fear of participating in car traffic that affects a person's lifestyle, including aspects such as an inability to participate in certain jobs due to the pathological avoidance of driving. The fear of driving may be triggered by specific driving situations, such as expressway driving or dense traffic. Driving anxiety can range from a mild cautious concern to a phobia.

The Somatic Symptom Scale - 8 (SSS-8) is a brief self-report questionnaire used to assess somatic symptom burden. It measures the perceived burden of common somatic symptoms. These symptoms were originally chosen to reflect common symptoms in primary care but they are relevant for a large number of diseases and mental disorders. The SSS-8 is a brief version of the popular Patient Health Questionnaire - 15 (PHQ-15).

The Screen for Child Anxiety Related Emotional Disorders (SCARED) is a self-report screening questionnaire for anxiety disorders developed in 1997. The SCARED is intended for youth, 9–18 years old, and their parents to complete in about 10 minutes. It can discriminate between depression and anxiety, as well as among distinct anxiety disorders. The SCARED is useful for generalized anxiety disorder, social anxiety disorder, phobic disorders, and school anxiety problems. Most available self-report instruments that measure anxiety in children look at general aspects of anxiety rather than Diagnostic and Statistical Manual of Mental Disorders (DSM) categorizations. The SCARED was developed as an instrument for both children and their parents that would encompass several DSM-IV and DSM-5 categorizations of the anxiety disorders: somatic/panic, generalized anxiety, separation anxiety, social phobia, and school phobia.

The Mood Disorder Questionnaire (MDQ) is a self-report questionnaire designed to help detect bipolar disorder. It focuses on symptoms of hypomania and mania, which are the mood states that separate bipolar disorders from other types of depression and mood disorder. It has 5 main questions, and the first question has 13 parts, for a total of 17 questions. The MDQ was originally tested with adults, but it also has been studied in adolescents ages 11 years and above. It takes approximately 5–10 minutes to complete. In 2006, a parent-report version was created to allow for assessment of bipolar symptoms in children or adolescents from a caregiver perspective, with the research looking at youths as young as 5 years old. The MDQ has become one of the most widely studied and used questionnaires for bipolar disorder, and it has been translated into more than a dozen languages.

The Child Mania Rating Scales (CMRS) is a 21-item diagnostic screening measure designed to identify symptoms of mania in children and adolescents aged 9–17 using diagnostic criteria from the DSM-IV, developed by Pavuluri and colleagues. There is also a 10-item short form. The measure assesses the child's mood and behavior symptoms, asking parents or teachers to rate how often the symptoms have caused a problem for the youth in the past month. Clinical studies have found the CMRS to be reliable and valid when completed by parents in the assessment of children's bipolar symptoms. The CMRS also can differentiate cases of pediatric bipolar disorder from those with ADHD or no disorder, as well as delineating bipolar subtypes. A meta-analysis comparing the different rating scales available found that the CMRS was one of the best performing scales in terms of telling cases with bipolar disorder apart from other clinical diagnoses. The CMRS has also been found to provide a reliable and valid assessment of symptoms longitudinally over the course of treatment. The combination of showing good reliability and validity across multiple samples and clinical settings, along with being free and brief to score, make the CMRS a promising tool, especially since most other checklists available for youths do not assess manic symptoms.

The nine-item Patient Health Questionnaire (PHQ-9) is a depressive symptom scale and diagnostic tool introduced in 2001 to screen adult patients in primary care settings. The instrument assesses for the presence and severity of depressive symptoms and a possible depressive disorder. The PHQ-9 is a component of the larger self-administered Patient Health Questionnaire (PHQ), but can be used as a stand-alone instrument. The PHQ is part of Pfizer's larger suite of trademarked products, called the Primary Care Evaluation of Mental Disorders (PRIME-MD). The PHQ-9 takes less than three minutes to complete. It is scored by simply adding up the individual items' scores. Each of the nine items reflects a DSM-5 symptom of depression. Primary care providers can use the PHQ-9 to screen for possible depression in patients.

The Somatic Symptom Disorder - B Criteria Scale (SSD-12) is a brief self-report questionnaire used to assess the B criteria of DSM-5 somatic symptom disorder, i.e. the patients’ perceptions of their symptom-related thoughts, feelings, and behaviors.

References

  1. 1 2 3 4 Spitzer RL, Kroenke K, Williams JB, Löwe B (May 2006). "A brief measure for assessing generalized anxiety disorder: the GAD-7". Archives of Internal Medicine. 166 (10): 1092–1097. doi: 10.1001/archinte.166.10.1092 . PMID   16717171.
  2. 1 2 Löwe B, Decker O, Müller S, Brähler E, Schellberg D, Herzog W, et al. (March 2008). "Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population". Medical Care. 46 (3): 266–274. doi:10.1097/mlr.0b013e318160d093. PMID   18388841. S2CID   16052239.
  3. ↑ Herr NR, Williams JW, Benjamin S, McDuffie J (July 2014). "Does this patient have generalized anxiety or panic disorder?: The Rational Clinical Examination systematic review". Jama. 312 (1): 78–84. doi:10.1001/jama.2014.5950. PMID   25058220.
  4. ↑ Zhong QY, Gelaye B, Zaslavsky AM, Fann JR, Rondon MB, Sánchez SE, et al. (2015-04-27). "Diagnostic Validity of the Generalized Anxiety Disorder - 7 (GAD-7) among Pregnant Women". PloS One. 10 (4): e0125096. Bibcode:2015PLoSO..1025096Z. doi: 10.1371/journal.pone.0125096 . PMC   4411061 . PMID   25915929.
  5. ↑ Swinson RP (December 2006). "The GAD-7 scale was accurate for diagnosing generalised anxiety disorder". Evidence-Based Medicine. 11 (6): 184. doi:10.1136/ebm.11.6.184. PMID   17213178. S2CID   42283551.
  6. ↑ Löwe B, Decker O, Müller S, Brähler E, Schellberg D, Herzog W, et al. (March 2008). "Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population". Medical Care. 46 (3): 266–274. doi:10.1097/MLR.0b013e318160d093. JSTOR   40221654. PMID   18388841. S2CID   16052239.
  7. ↑ Dugas MJ, Charette CA, Gervais NJ (2018). "A Guide to Assessments That Work". Generalized Anxiety Disorder (2nd ed.). Oxford University Press. pp. 293–310. doi:10.1093/med-psych/9780190492243.003.0014.
  8. ↑ Plummer F, Manea L, Trepel D, McMillan D (2016-03-01). "Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis". General Hospital Psychiatry. 39: 24–31. doi:10.1016/j.genhosppsych.2015.11.005. PMID   26719105.
  9. ↑ Kroenke K, Spitzer RL, Williams JB, Löwe B (2010-07-01). "The Patient Health Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: a systematic review". General Hospital Psychiatry. 32 (4): 345–359. doi:10.1016/j.genhosppsych.2010.03.006. PMID   20633738.
  10. ↑ Dear BF, Titov N, Sunderland M, McMillan D, Anderson T, Lorian C, et al. (September 2011). "Psychometric comparison of the generalized anxiety disorder scale-7 and the Penn State Worry Questionnaire for measuring response during treatment of generalised anxiety disorder". Cognitive Behaviour Therapy. 40 (3): 216–227. doi:10.1080/16506073.2011.582138. PMID   21770844.
  11. ↑ Simpson W, Glazer M, Michalski N, Steiner M, Frey BN (August 2014). "Comparative efficacy of the generalized anxiety disorder 7-item scale and the Edinburgh Postnatal Depression Scale as screening tools for generalized anxiety disorder in pregnancy and the postpartum period". Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 59 (8): 434–440. doi:10.1177/070674371405900806. PMC   4143300 . PMID   25161068.
  12. ↑ Peters L, Peters A, Andreopoulos E, Pollock N, Pande RL, Mochari-Greenberger H (March 2021). "Comparison of DASS-21, PHQ-8, and GAD-7 in a virtual behavioral health care setting". Heliyon. 7 (3): e06473. doi: 10.1016/j.heliyon.2021.e06473 . PMC   8010403 . PMID   33817367.
  13. ↑ Guzick A, Storch EA, Smárason O, Minhajuddin A, Drummond K, Riddle D, et al. (February 2024). "Psychometric properties of the GAD-7 and PROMIS-Anxiety-4a among youth with depression and suicidality: Results from the Texas youth depression and suicide research network". Journal of Psychiatric Research. 170: 237–244. doi:10.1016/j.jpsychires.2023.12.033. PMID   38169247.
  14. ↑ Wild B, Eckl A, Herzog W, Niehoff D, Lechner S, Maatouk I, et al. (October 2014). "Assessing generalized anxiety disorder in elderly people using the GAD-7 and GAD-2 scales: results of a validation study". The American Journal of Geriatric Psychiatry. 22 (10): 1029–1038. doi:10.1016/j.jagp.2013.01.076. PMID   23768681.
  15. ↑ Spitzer RL, Kroenke K, Williams JB, Löwe B (May 2006). "A brief measure for assessing generalized anxiety disorder: the GAD-7". Archives of Internal Medicine. 166 (10): 1092–1097. doi: 10.1001/archinte.166.10.1092 . PMID   16717171.
  16. ↑ Plummer F, Manea L, Trepel D, McMillan D (2016). "Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis". General Hospital Psychiatry. 39: 24–31. doi:10.1016/j.genhosppsych.2015.11.005. PMID   26719105.
  17. ↑ De Man J, Absetz P, Sathish T, Desloge A, Haregu T, Oldenburg B, et al. (2021-05-13). "Are the PHQ-9 and GAD-7 Suitable for Use in India? A Psychometric Analysis". Frontiers in Psychology. 12: 676398. doi: 10.3389/fpsyg.2021.676398 . PMC   8155718 . PMID   34054677.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.